Why Molecular Testing Must Come Before Any Chemotherapy Decision

---

This point cannot be stated strongly enough: the first decision in colon cancer chemotherapy is not which chemotherapy to give. It is which tests to run on the tumour tissue before any treatment begins. The right chemotherapy for one patient is the wrong chemotherapy for another — and the difference is determined entirely by the tumour's molecular characteristics, not by its stage or location.

There are four molecular tests that are mandatory before chemotherapy decisions are made in Stage 3 or Stage 4 colon cancer. All four are available at India's major oncology centres, processed in-house, and return results within 5 to 7 days. The total cost for all four tests is USD 280 to 460 in India — roughly one-tenth of what the same panel costs in the United States.

Adjuvant Chemotherapy for Stage 3 — FOLFOX and CAPOX Explained

---

Adjuvant chemotherapy means chemotherapy given after surgery when the cancer has been completely removed. The tumour is gone. The lymph nodes have been dissected. The pathology report shows clear margins. So why chemotherapy? Because cancer cells are not visible to the naked eye, and the question after Stage 3 surgery is not whether the visible cancer has been removed — it has been. The question is whether microscopic deposits of cancer cells have already entered the lymphatic system or bloodstream and lodged somewhere in the body before the operation took place. These deposits are too small to detect on any scan. Adjuvant chemotherapy destroys them.

The evidence for adjuvant chemotherapy in Stage 3 colon cancer is among the most robustly established in oncology. The MOSAIC trial — the landmark randomised study that established FOLFOX as the standard adjuvant regimen — demonstrated a 23 percent reduction in recurrence risk and a 10 percentage point improvement in five-year overall survival compared to surgery alone. That is not a marginal benefit. For a Stage 3C patient whose five-year survival without chemotherapy might be 30 percent, that improvement means the difference between one-in-three and one-in-two odds of long-term survival.

FOLFOX — the backbone of Stage 3 adjuvant treatment

FOLFOX is an acronym for the three drugs it contains: FOLinic acid (leucovorin), F-fluorouracil (5-FU), and OXaliplatin. The oxaliplatin is the pharmacologically active agent that provides the survival benefit. Leucovorin modulates the activity of 5-FU to enhance its effect. 5-FU itself has direct anti-tumour activity.

A single FOLFOX cycle takes place over two days. On day one, you attend the infusion centre at the hospital. The oxaliplatin is given as a 2-hour intravenous infusion, followed by the leucovorin, followed by a bolus of 5-FU. A portable infusion pump is then connected to your port-a-cath and delivers the 46-hour 5-FU infusion continuously. You take the pump home overnight. On day three, you return to the clinic for the pump to be disconnected and your port flushed. The cycle then repeats every two weeks. Twelve cycles — which is how many FOLFOX cycles constitute the standard six-month course — means this routine repeats twelve times over twenty-four weeks.

One of the most practical questions for international patients is: what happens between cycles? Between cycles you are at home — or in your accommodation near the hospital if you are completing your cycles in India. You are not in hospital. You are living your life, managing side effects, and attending blood test appointments before each cycle to confirm your counts are adequate to proceed. The two-day cycle structure of FOLFOX is manageable for most patients, and the 12-day gap between cycles allows recovery between treatments.

CAPOX — the oral alternative with fewer clinic visits

CAPOX replaces the intravenous 5-FU and leucovorin of FOLFOX with oral capecitabine tablets. The oxaliplatin component remains as an intravenous infusion. Each CAPOX cycle involves one clinic visit for the oxaliplatin infusion on day one, then capecitabine tablets taken at home twice daily for 14 days, followed by a 7-day rest. The cycle repeats every three weeks, and a full course is eight cycles over six months.

For international patients using the hybrid model — starting in India and completing at home — CAPOX offers a practical advantage. You need only one clinic visit every three weeks for the oxaliplatin infusion. The capecitabine tablets can be dispensed and taken at home. In countries where intravenous infusion centres are less accessible or where the nursing infrastructure for pump management is limited, CAPOX is often a more reliable option than FOLFOX. The survival outcomes of CAPOX and FOLFOX are equivalent — confirmed by the XELOXA trial and multiple meta-analyses.

Stage 4 Chemotherapy — FOLFIRI, Bevacizumab, and Cetuximab

---

For Stage 4 colon cancer patients who are not MSI-H, chemotherapy is not a fixed-duration course — it continues for as long as it is working and you can tolerate it. The goals are different to adjuvant chemotherapy: control the cancer, preserve quality of life, shrink tumours enough to allow surgery in selected patients, and extend survival. The drug combinations available in India for Stage 4 disease are the same as those used at Memorial Sloan Kettering, the Royal Marsden, and MD Anderson.

FOLFOX as first-line Stage 4 treatment

FOLFOX is also used as first-line chemotherapy for Stage 4 colon cancer. The same drug combination that is given adjuvantly after Stage 3 surgery is given as primary treatment for Stage 4 patients when the cancer cannot be surgically removed or before surgery is attempted to downstage the disease. In Stage 4, FOLFOX is almost always combined with a targeted agent — bevacizumab for all patients regardless of RAS status, or cetuximab for the specific subgroup of patients who are RAS wild-type with a left-sided primary tumour.

FOLFIRI — second-line after FOLFOX progression

When colon cancer progresses on FOLFOX — meaning the tumours continue to grow despite treatment — FOLFIRI is the standard second-line chemotherapy. FOLFIRI replaces oxaliplatin with irinotecan, a drug that works through a different mechanism and therefore retains activity in tumours that have become resistant to oxaliplatin. The leucovorin and 5-FU components remain. A targeted agent — bevacizumab if not previously used with FOLFOX, or aflibercept, ramucirumab, or regorafenib in specific situations — is typically added.

FOLFIRI carries a different side effect profile to FOLFOX — the peripheral neuropathy that builds cumulatively with oxaliplatin does not occur with irinotecan. Instead, the characteristic FOLFIRI side effects are diarrhoea, hair thinning, and fatigue. The diarrhoea can be significant and requires specific management with loperamide. Importantly, patients who have developed significant oxaliplatin-induced neuropathy during FOLFOX often experience symptom improvement after switching to FOLFIRI because oxaliplatin is no longer being administered.

Bevacizumab — the universal add-on

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor — the protein tumours use to grow new blood vessels to feed themselves. By cutting off this blood supply, bevacizumab slows tumour growth and enhances the effectiveness of the chemotherapy drugs given alongside it. It is added to either FOLFOX or FOLFIRI and improves both progression-free and overall survival in Stage 4 colon cancer regardless of the tumour's RAS mutation status.

In India, bevacizumab is available as both the originator drug (Avastin, manufactured by Roche) and as biosimilar versions manufactured by Indian pharmaceutical companies and approved by the Indian drug regulator CDSCO. The biosimilar versions — Bevatas, Bevacirel, Abevmy among others — have been rigorously evaluated for equivalence and are used across India's leading oncology centres. The clinical outcomes with biosimilar bevacizumab are identical to the originator drug. The cost difference is significant: biosimilar bevacizumab in India costs USD 600 to 900 per infusion, compared to USD 4,000 to 7,000 for the originator in the United States.

Cetuximab — only for the right patients

Cetuximab targets the epidermal growth factor receptor — EGFR — which is overexpressed on the surface of many colon cancer cells and drives tumour growth. It works powerfully when it works — but it only works in a specific subgroup of patients. The criteria for cetuximab eligibility are: RAS wild-type (KRAS and NRAS both unmutated), BRAF wild-type (no V600E mutation), and left-sided primary tumour location (descending colon, sigmoid, rectosigmoid). Patients who do not meet all three criteria should not receive cetuximab — it will provide no benefit and may cause significant skin toxicity.

When cetuximab is given to the right patients — RAS wild-type, BRAF wild-type, left-sided — it is one of the most effective drugs in colorectal oncology. The CRYSTAL trial and OPUS trial both demonstrated significantly improved response rates, progression-free survival, and overall survival when cetuximab was added to FOLFIRI or FOLFOX in this specific population. Some patients achieve tumour shrinkage dramatic enough to allow surgical removal of previously inoperable metastases — a genuine chance of cure in selected Stage 4 patients.

Immunotherapy for MSI-H Colon Cancer — Pembrolizumab

---

For the approximately 5 percent of Stage 4 colon cancer patients whose tumours are MSI-H, immunotherapy with pembrolizumab has replaced chemotherapy as the standard first-line treatment. This is one of the most significant advances in colorectal oncology in the last decade, and understanding it matters enormously if your tumour is MSI-H.

MSI-H — microsatellite instability-high — means the tumour has a defect in its DNA mismatch repair machinery. As a result, it accumulates a very large number of mutations compared to MSS (microsatellite stable) tumours. This high mutation burden makes MSI-H tumours uniquely recognisable to the immune system — and uniquely responsive to drugs that remove the brakes the tumour uses to prevent immune attack. Pembrolizumab is one of those drugs. It blocks the PD-1 checkpoint protein on immune T-cells, restoring their ability to attack the cancer.

The KEYNOTE-177 trial — which directly compared pembrolizumab to FOLFOX plus bevacizumab as first-line treatment for MSI-H Stage 4 colon cancer — produced results that changed practice immediately. Pembrolizumab achieved a median progression-free survival of 16.5 months versus 8.2 months for chemotherapy. Forty-three percent of patients on pembrolizumab had not progressed at two years — compared to 33 percent on chemotherapy. Pembrolizumab produced complete responses — complete disappearance of all measurable disease — in a meaningful proportion of patients. Some of these responses appear durable over years.

Pembrolizumab is given as a 30-minute intravenous infusion every three weeks as an outpatient. It does not cause the nausea, neuropathy, or bone marrow suppression of conventional chemotherapy. Its side effect profile — immune-related adverse events affecting the thyroid, liver, lungs, skin, or joints — is different in nature and generally less predictable in timing, but manageable at experienced centres. India's leading oncology centres have substantial experience managing immunotherapy toxicity, and pembrolizumab is available at all of GAF Healthcare's partner hospitals.

The Hybrid Model — Start in India, Complete at Home

---

The hybrid treatment model is how the majority of international patients receiving colon cancer chemotherapy through GAF Healthcare approach their treatment — and it works reliably for patients from Nigeria, Kenya, Bangladesh, the UAE, the UK, and every other country in our patient base. The model solves a genuine logistical problem: surgery in India is the right choice, but staying in India for six months of chemotherapy is impractical and expensive for almost everyone.

Here is precisely how it works. Surgery is performed in India at a JCI-accredited hospital. After the histopathology report confirms Stage 3 disease, the oncologist meets with you to confirm the chemotherapy protocol — FOLFOX or CAPOX, with specific dose calculations based on your body surface area. A port-a-cath is inserted as a minor procedure under local anaesthetic — this subcutaneous device provides permanent reliable venous access for all chemotherapy infusions without needing a new cannula each time. You begin the first two to four chemotherapy cycles in India, which serves three purposes: establishing that you can tolerate the drugs, confirming the dose is appropriate, and allowing the oncology team to adjust the protocol if needed based on your response and side effects.

You then fly home with a discharge package that contains everything your local oncologist needs: the operative report and histopathology with stage and molecular profile, the chemotherapy protocol with drug names, doses per square metre of body surface area, cycle schedule, pre-medication regimen, anti-emetic protocol, growth factor requirements if applicable, and the monitoring blood test schedule before each cycle. The document is written specifically for an oncologist who does not know your history — it is self-contained, and any competent oncologist anywhere in the world can implement it.

Your India oncologist remains available for video consultation throughout your treatment course. If your local oncologist has questions about dose modification for significant side effects, or about the management of a specific adverse event, they can contact the India team directly. GAF Healthcare coordinates this communication. When your treatment course is complete — typically after twelve cycles of FOLFOX or eight cycles of CAPOX — the India oncologist is copied on your surveillance scan report to complete the clinical follow-up.

Complete Chemotherapy Cost Reference — India vs the World

---

The costs below are based on 2026 tariff data from GAF Healthcare's partner hospitals. All per-cycle costs include the chemotherapy drugs, infusion nursing, chair time, pre-medications, and standard monitoring blood tests. They do not include port-a-cath insertion (USD 400 to 700, a one-time cost) or specialist oncology consultation fees (USD 50 to 120 per consultation).

Regimen	Per cycle India	Full course India	Per cycle USA	For
FOLFOX (12 cycles × 6 months)	$400–$700	$3,000–$5,500	$8,000–$15,000	Stage 3 adj · Stage 4
CAPOX (8 cycles × 6 months)	$380–$650	$2,800–$5,000	$7,000–$13,000	Stage 3 adj · Stage 4
FOLFIRI (per cycle)	$350–$750	Ongoing	$7,000–$14,000	2nd-line Stage 4
Bevacizumab add-on (per cycle)	$600–$900	+$7,200–$10,800	$4,000–$7,000	All RAS types Stage 4
Cetuximab add-on (per cycle)	$700–$1,100	Ongoing	$6,000–$10,000	RAS WT left-sided
Pembrolizumab (per cycle)	$1,200–$1,800	Ongoing	$10,000–$16,000	MSI-H Stage 4
Encorafenib + Cetuximab (per cycle)	$2,800–$4,200	Ongoing	$18,000–$28,000	BRAF V600E Stage 4

Sources: GAF Healthcare Hospital Cost Database 2026 · Apollo, Medanta, Fortis, Max Cancer Centre oncology tariffs · CMS Hospital Price Transparency Data USA 2026 · NHS Chemotherapy Reference Costs 2025

"I started my FOLFOX at Apollo Chennai — two cycles in India, then flew home to Accra with the protocol. My oncologist here followed it exactly. The India team answered his questions on WhatsApp. I finished all twelve cycles. The total cost including surgery was under $15,000. The same treatment in the UK was quoted at £95,000."

Side Effects — What to Expect and How They Are Managed

---

Chemotherapy side effects are real and they are managed. Understanding what to expect removes the fear of the unknown and allows you to take an active role in monitoring your own response to treatment. The following covers the most significant side effects of the main colon cancer regimens used in India.

Side effect	Which drugs	What it feels like	How it is managed
Peripheral neuropathy	Oxaliplatin (FOLFOX/CAPOX)	Tingling, numbness, or pain in hands and feet. Worsens with cumulative cycles.	Dose reduction or oxaliplatin discontinuation if Grade 2–3. Resolves over months after treatment ends for most patients.
Cold-triggered neuropathy	Oxaliplatin	Discomfort touching cold objects or breathing cold air — characteristic of oxaliplatin. Usually resolves between cycles.	Avoid cold exposure for 5 days after each cycle. Warm gloves and socks. Typically manageable.
Nausea and vomiting	All regimens	Typically days 1–3 after each cycle. Rarely severe with modern anti-emetics.	5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), dexamethasone. Well-controlled in most patients.
Diarrhoea	FOLFIRI, Capecitabine	Watery stools, frequent and sometimes urgent. Can be significant with irinotecan.	Loperamide at first sign. Dose reduction if persistent Grade 2+. Hydration maintenance essential.
Fatigue	All regimens	Cumulative tiredness that builds over the course of treatment. Typically manageable but real.	Rest, moderate exercise, anaemia management if present. Improves significantly after treatment completion.
Neutropenia	All regimens	Low white blood cell count — no symptoms but increased infection risk. Detected by pre-cycle blood test.	G-CSF injections if clinically indicated. Cycle delay if counts too low. Dose reduction if recurrent.
Hand-foot syndrome	Capecitabine (CAPOX)	Redness, soreness, peeling of palms and soles. Typically mild to moderate with correct moisturiser use.	Regular moisturiser from day one of treatment. Dose reduction if Grade 2+. Resolves after treatment.
Skin toxicity	Cetuximab	Acne-like rash on face and chest — paradoxically associated with cetuximab response. Usually manageable.	Topical and oral antibiotics, moisturisers, sun protection. Paradoxically — rash severity correlates with treatment response.

Sources: NCCN Guidelines Toxicity Management 2025 · ESMO Clinical Practice Guidelines 2024 · GAF Healthcare clinical protocol documentation

How to Get Started as an International Patient

---

Whether you are planning surgery plus chemotherapy as a complete package or you have already had surgery elsewhere and need chemotherapy at an experienced centre, the process starts the same way.

1. 1

   Send your records — including molecular profiling results

   Send GAF Healthcare your colonoscopy and biopsy pathology report, staging CT, CEA blood test, and — critically — any molecular profiling results you have. If you have not had KRAS, NRAS, BRAF, MSI, and HER2 testing, tell us. We can arrange this from your biopsy tissue blocks before you travel and use the results to determine your chemotherapy protocol before you arrive.

2. 2

   Receive chemotherapy protocol recommendation within 48 hours

   GAF Healthcare forwards your records to a GI medical oncologist at a matched hospital. You receive a written chemotherapy protocol recommendation — including which regimen, which targeted agent if applicable, cycle schedule, and itemised cost estimate — within 48 to 72 hours. No payment required at this stage.

3. 3

   Medical visa and travel planning

   GAF Healthcare provides the medical visa support letter. India's e-Medical Visa is valid for one year with multiple entries — important if you return for repeat cycles or surveillance. For patients coming only for chemotherapy without prior surgery in India, the visa process is identical.

4. 4

   Arrival, pre-chemo workup, and port-a-cath

   Within 24 to 48 hours of arrival the oncology team reviews your records, confirms molecular profiling, and performs any additional baseline tests. If you do not already have a port-a-cath, it is inserted as a minor day-procedure before your first cycle. The first chemotherapy cycle typically begins within 5 to 7 days of arrival.

5. 5

   Complete 2 to 4 cycles in India

   You complete the first two to four cycles at the hospital infusion suite. Your oncologist monitors your blood counts, adjusts doses if needed, and confirms you are tolerating the regimen before you fly home. Total India stay for surgery plus starting chemotherapy is typically 30 to 35 days.

6. 6

   Fly home with the complete discharge protocol

   You leave India with the complete discharge package described above. Your local oncologist continues the protocol at home. Your India oncologist is available for video consultation throughout. GAF Healthcare coordinates communication between your India and home teams.